Protein chemistry and peptide synthesis have been a prominent feature of the Program's activities since its inception in 1968. Originally, these were carried out as a part of a component Project aimed at the structural analysis and study of the structure-activity relations of parathyroid hormone and calcitonin. Besides the earliest active synthetic calcium-regulating peptides, fundamental and enduring contributions to sequencing and synthetic methodologies emerged from these investigations. The increasing versatility of these chemical methods brought steadily expanding benefits to all of the projects;to meet the resulting needs, a separate Core was established in 1979. In addition to continued development of synthetic PTH agonists and antagonists, the Core proceeded to fulfill such diverse roles as identifying products of in vivo PTH metabolism, calibrating standards for a range of biological and immunological assays, characterizing and microsequencing recombinant expression products and biosynthetically labeled proteins, and characterizing membrane proteins in conjunction with the successful effort to purify the PTH/PTHrP receptor. With the move of the Endocrine Unit into the Wellman (now Their) Building laboratory in the mid-1980's came the first step in the process of resource sharing that continues to this day to bring major benefits to both the Program and the NIH. By formally consolidating in 1993 into a common analytical-synthesis facility with the Molecular Endocrinology and Reproductive Endocrine Units, followed by the Partners AIDS Research Center, the Core gained important new capabilities including gas-phase sequencing, microbore HPLC and enhanced synthesis capacity. Then, as now, operating costs were carefully allocated among the individual projects and investigators according to utilization, but the benefits realized from widened access to methodology, depth of experience, flexibility in personnel deployment and economies of scale were clearly apparent at the time of the last Program Project renewal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK011794-43
Application #
8208816
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
43
Fiscal Year
2011
Total Cost
$184,034
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Mitchell, Deborah M; J├╝ppner, Harald; Burnett-Bowie, Sherri-Ann M (2017) FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab 102:1151-1160
Li, Yuwen; Caballero, Daniel; Ponsetto, Julian et al. (2017) Response of Npt2a knockout mice to dietary calcium and phosphorus. PLoS One 12:e0176232
Leaf, David E; Jacob, Kirolos A; Srivastava, Anand et al. (2017) Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol 28:1877-1885
Knab, Vanessa M; Corbin, Braden; Andrukhova, Olena et al. (2017) Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels. Endocrinology 158:1130-1139
Guo, Jun; Khatri, Ashok; Maeda, Akira et al. (2017) Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment. J Bone Miner Res 32:86-98
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2017) Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J Bone Miner Res 32:892-901
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107

Showing the most recent 10 out of 208 publications